Jeffrey Conn Archives
Nov. 26, 2018—Ancora Innovation, LLC, the new collaboration between Vanderbilt and Deerfield Management established earlier this year, has completed its inaugural proposal review process and announced two projects selected for funding.
Jan. 18, 2018—Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson’s disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.
Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Dec. 7, 2017—Eight current faculty members at Vanderbilt have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
Oct. 12, 2017—P. Jeffrey Conn, Ph.D., founding director of the Vanderbilt Center for Neuroscience Drug Discovery, has won a 2017 Research & Hope Award from the Pharmaceutical Research and Manufacturers of America (PhRMA) for outstanding research in the area of mental health.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Oct. 29, 2015—A compound developed by researchers at Vanderbilt University can improve early symptoms and delay progression of Huntington’s disease in a mouse model of the neurodegenerative disorder.
Oct. 8, 2015—Five current faculty members at Vanderbilt University Medical Center have made this year’s list of scientists whose papers have been cited most frequently by others.
May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
Aug. 7, 2014—Vanderbilt University’s P. Jeffrey Conn, Ph.D., has won a Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke for discoveries that could lead to new treatments for anxiety, schizophrenia and other brain disorders.